Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.86
GRFS's Cash to Debt is ranked higher than
65% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GRFS: 4.86 )
GRFS' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 4.86

Equity to Asset 0.31
GRFS's Equity to Asset is ranked higher than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GRFS: 0.31 )
GRFS' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.37
Current: 0.31

0.28
0.37
Interest Coverage 3.07
GRFS's Interest Coverage is ranked lower than
52% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 3.07 )
GRFS' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 3.07

1.56
18.28
F-Score: 7
Z-Score: 2.21
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 25.56
GRFS's Operating margin (%) is ranked higher than
94% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. GRFS: 25.56 )
GRFS' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 25.56

15.53
26.85
Net-margin (%) 13.32
GRFS's Net-margin (%) is ranked higher than
90% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. GRFS: 13.32 )
GRFS' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 13.32

2.8
16.2
ROE (%) 18.89
GRFS's ROE (%) is ranked higher than
95% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. GRFS: 18.89 )
GRFS' s 10-Year ROE (%) Range
Min: 4.27   Max: 18.34
Current: 18.89

4.27
18.34
ROA (%) 6.12
GRFS's ROA (%) is ranked higher than
92% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. GRFS: 6.12 )
GRFS' s 10-Year ROA (%) Range
Min: 1.34   Max: 6.51
Current: 6.12

1.34
6.51
ROC (Joel Greenblatt) (%) 40.99
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. GRFS: 40.99 )
GRFS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.07   Max: 42.94
Current: 40.99

19.07
42.94
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GRFS Guru Trades in Q4 2013

Caxton Associates 35,305 sh (New)
Mario Gabelli 29,977 sh (+25.07%)
Ron Baron 27,000 sh (unchged)
Steve Mandel Sold Out
Steven Cohen Sold Out
John Paulson 19,823,407 sh (-0.07%)
Jim Simons 550,702 sh (-58.98%)
» More
Q1 2014

GRFS Guru Trades in Q1 2014

Steven Cohen 456,098 sh (New)
Ron Baron 44,757 sh (+65.77%)
John Paulson 19,814,807 sh (-0.04%)
Mario Gabelli 29,777 sh (-0.67%)
Jim Simons 493,102 sh (-10.46%)
Caxton Associates 25,800 sh (-26.92%)
» More
Q2 2014

GRFS Guru Trades in Q2 2014

Caxton Associates 87,571 sh (+239.42%)
Jim Simons 526,802 sh (+6.83%)
Steven Cohen 112,300 sh (unchged)
John Paulson 19,605,181 sh (-1.06%)
Ron Baron 42,800 sh (-4.37%)
Mario Gabelli 25,177 sh (-15.45%)
» More
Q3 2014

GRFS Guru Trades in Q3 2014

Mario Gabelli 25,177 sh (unchged)
John Paulson 19,604,981 sh (unchged)
Ron Baron 42,800 sh (unchged)
Caxton Associates Sold Out
Jim Simons 365,002 sh (-30.71%)
Steven Cohen 22,700 sh (-79.79%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Add 65.77%$34.91 - $42.83 $ 33.41-16%44757
Steve Mandel 2013-12-31 Sold Out 0.6%$28.78 - $36.23 $ 33.414%0
Mario Gabelli 2013-12-31 Add 25.07%$28.78 - $36.23 $ 33.414%29977
Ron Baron 2013-06-30 Reduce -26.73%$25.84 - $31.23 $ 33.4119%27000
Steve Mandel 2012-12-31 Add 1919.04%0.67%$22.46 - $25.27 $ 33.4143%4437327
John Paulson 2012-12-31 Add 23.16%0.6%$22.46 - $25.27 $ 33.4143%20179935
Ron Baron 2012-12-31 Reduce -22.3%$22.46 - $25.27 $ 33.4143%38850
John Paulson 2012-09-30 Add 46.23%0.98%$9.66 - $22.92 $ 33.4183%16385799
Steve Mandel 2012-09-30 New Buy0.03%$9.66 - $22.92 $ 33.4183%219774
Mario Gabelli 2012-09-30 New Buy$9.66 - $22.92 $ 33.4183%27820
Ron Baron 2012-09-30 Reduce -50%$9.66 - $22.92 $ 33.4183%50000
Mario Gabelli 2012-06-30 Sold Out 0.0031%$7.8 - $9.68 $ 33.41282%0
Andreas Halvorsen 2012-03-31 Sold Out 0.1%$5.38 - $7.8 $ 33.41431%0
Ron Baron 2012-03-31 Add 25%$5.38 - $7.8 $ 33.41431%100000
Steve Mandel 2011-12-31 Sold Out 0.37%$4.52727 - $6.06364 $ 33.41520%0
Steve Mandel 2011-09-30 New Buy0.37%$5.02 - $7.39 $ 33.41423%7067971
John Paulson 2011-09-30 Reduce -21.85%0.08%$5.02 - $7.39 $ 33.41423%11150000
Ron Baron 2011-09-30 New Buy$5.02 - $7.39 $ 33.41423%65000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.90
GRFS's P/E(ttm) is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GRFS: 26.90 )
GRFS' s 10-Year P/E(ttm) Range
Min: 19.05   Max: 102.43
Current: 26.9

19.05
102.43
P/B 4.40
GRFS's P/B is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. GRFS: 4.40 )
GRFS' s 10-Year P/B Range
Min: 2.33   Max: 6.76
Current: 4.4

2.33
6.76
P/S 3.50
GRFS's P/S is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. GRFS: 3.50 )
GRFS' s 10-Year P/S Range
Min: 1.87   Max: 6.66
Current: 3.5

1.87
6.66
PFCF 18.00
GRFS's PFCF is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GRFS: 18.00 )
GRFS' s 10-Year PFCF Range
Min: 16.28   Max: 1198.5
Current: 18

16.28
1198.5
EV-to-EBIT 12.04
GRFS's EV-to-EBIT is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GRFS: 12.04 )
GRFS' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 47
Current: 12.04

11.7
47
PEG 0.94
GRFS's PEG is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GRFS: 0.94 )
GRFS' s 10-Year PEG Range
Min: 0   Max: 2
Current: 0.94

0
2
Current Ratio 2.75
GRFS's Current Ratio is ranked higher than
64% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. GRFS: 2.75 )
GRFS' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.26
Current: 2.75

2.19
3.26
Quick Ratio 1.59
GRFS's Quick Ratio is ranked higher than
59% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GRFS: 1.59 )
GRFS' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.88
Current: 1.59

1.15
1.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
GRFS's Dividend Yield is ranked higher than
68% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. GRFS: 1.40 )
GRFS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 0.6
Current: 1.4

0.38
0.6
Dividend Payout 0.12
GRFS's Dividend Payout is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GRFS: 0.12 )
GRFS' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.59
Current: 0.12

0.19
0.59
Yield on cost (5-Year) 1.40
GRFS's Yield on cost (5-Year) is ranked higher than
58% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. GRFS: 1.40 )
GRFS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 0.6
Current: 1.4

0.38
0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.80
GRFS's Price/Median PS Value is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GRFS: 0.80 )
GRFS' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 1.59
Current: 0.8

0.56
1.59
Earnings Yield (Greenblatt) 8.30
GRFS's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GRFS: 8.30 )
GRFS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.6
Current: 8.3

2.1
8.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GIFLF.USA, GIKLY.USA, GRF.P.Spain, 0EM7.UK, GRF.Spain, GIFOF.USA, G0FB.Germany, OZT.Germany,
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Grifols introduces new 40-g IVIG vial size for GAMUNEX-C Dec 01 2014
3 Stocks Raising The Drugs Industry Higher Nov 04 2014
Grifols’ net profit increases by 26.9% to 339 million euros in the nine months to September 2014... Nov 04 2014
Investigating inhibitor development in patients with Hemophilia A Oct 17 2014
3 Stocks Boosting The Drugs Industry Higher Oct 16 2014
Grifols presents its GATRA scholarship program to promote research on antithrombin therapy Oct 15 2014
3 Health Services Stocks Moving The Industry Upward Aug 20 2014
3 Stocks Underperforming Today In The Health Services Industry Aug 12 2014
Many Leading Stocks Damaged As Market Tumbles Broadly Jul 31 2014
Stocks Work Off Session Lows; GoPro Bucks Weakness Jul 31 2014
Argentina Default Hits Futures; OpenText Spikes, Grifols Dives Jul 31 2014
Nasdaq Leads Late Gains; S&P 500, Dow Erase Losses Jul 11 2014
Grifols SA Stock Upgraded (GRFS) Jul 08 2014
Stock Futures Point Lower; GasLog, Grifols, Kapstone Lag Jul 08 2014
Stocks Futures: Quiet And Mixed; Employers Hire Heavily In June Jul 03 2014
GRFS, OCR And A, 3 Health Services Stocks Pushing The Industry Lower Jul 02 2014
Grifols Struggles After Report Of Possible Violations Jun 25 2014
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% Jun 24 2014
Major Indexes Lower Near Midday; Matador Resources Rallies Jun 23 2014
Grifols shares off lows, remain down over 2% Jun 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK